NOTE

Serum Relaxin in Patients with Invasive Mole, Choriocarcinoma and Persistent Trophoblastic Disease

KATSUYOSHI SEKI, TADASHI UESATO AND KOICHI KATO

Department of Obstetrics and Gynecology, National Defense Medical College, Namiki 3-2, Tokorozawa, Saitama 359

Human chorionic gonadotropin (hCG) is considered to be one of the factors which regulate relaxin secretion in humans. Serum immunoreactive relaxin levels are increased and are detectable by radioimmunoassay both in normal and molar pregnancy. Circulating hCG levels are increased in trophoblastic disease. In the present study, relaxin and hCG levels were sequentially measured in patients with invasive mole, choriocarcinoma and persistent trophoblastic disease. Serum relaxin levels were detectable by radioimmunoassay in these patients before treatment, though they were significantly lower than in normal pregnancy. The corpus luteum of pregnancy is the main source of circulating relaxin in normal pregnancy. The existence of a corpus luteum was confirmed in the 2 patients who underwent laparotomy. Consequently, the corpus luteum may also be the main source of circulating relaxin in trophoblastic disease. Parallel changes in hCG and relaxin levels were observed during the courses of trophoblastic disease. The finding suggests that relaxin secretion is dependent on hCG stimulation in trophoblastic disease in the presence of corpus luteum.

Human chorionic gonadotropin (hCG) is considered to be one of the factors which regulate relaxin secretion in humans (Quagliarello et al., 1979; Quagliarello et al., 1980; Weiss et al., 1976). Serum immunoreactive relaxin levels are increased and detectable by radioimmunoassay (RIA) both in normal (O'Byrne et al., 1978) and molar pregnancy (Seki et al., 1986). Circulating levels of hCG are increased in patients with invasive mole or choriocarcinoma as in patients with hydatidiform mole. Consequently, the amount of serum relaxin may also be increased in such patients. We now report circulating levels of relaxin and hCG sequentially measured in patients with invasive mole, choriocarcinoma and persistent trophoblastic disease.

Materials and Methods

The subjects of this study were 2 patients with invasive mole, 2 patients with choriocarcinoma and 2 patients with persistent trophoblastic disease. Luteal cysts were detected in none of them. In 5 of the 6 patients, serum relaxin and hCG levels were sequentially measured by RIA before and after the initiation of therapy. In the remaining 1 patient with invasive mole, relaxin and hCG levels were measured only before therapy. Relaxin was measured by RIA (Sherwood et al., 1975; O'Byrne and
Steinetz, 1976) as previously described (Seki et al., 1985). hCG was measured with RIA kits obtained from Commissariat à l'Energie Atomique, France. The sensitivity of the hCG assay was 2.0 mIU/ml. Statistical analysis was performed using signed rank test. Serum hCG and relaxin concentrations in patients with invasive mole, choriocarcinoma and persistent trophoblastic disease were compared with those in 31 normal women during the first trimester of pregnancy (average 11.2 weeks of pregnancy; range nine to 14) or with those in 7 patients with hydatidiform mole, which had previously been reported elsewhere (Seki et al., 1986).

Table 1. Serum concentrations of relaxin and hCG (median and range) in patients with invasive mole, choriocarcinoma and persistent trophoblastic disease before treatment (n=6), patients with hydatidiform mole (n=7) and normal women during the first trimester of pregnancy (n=31).

<table>
<thead>
<tr>
<th>Invasive Mole</th>
<th>Choriocarcinoma</th>
<th>Persistent</th>
<th>Trophoblastic</th>
<th>Disease</th>
<th>Hydatidiform</th>
<th>Mole</th>
<th>Normal</th>
<th>Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relaxin (ng/ml)</td>
<td>0.31 (0.20–0.46)</td>
<td>0.70 (0.60–1.03)*</td>
<td>0.73 (0.49–0.97)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hCG (IU/ml)</td>
<td>3.5 (1.1–340)</td>
<td>420 (290–650)*</td>
<td>76 (25–166)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p < 0.01 vs patients with invasive mole, choriocarcinoma and persistent trophoblastic disease.

Fig. 1. A 33-year-old woman, gravida 2, para 2, underwent evacuation of a hydatidiform mole in June, 1984. Because of the rising hCG titers, she was referred to us on September 14, 1984. She underwent a total hysterectomy and right salpingo-oophorectomy (TAH-RSO) on October 15, 1984. Pathologic examination revealed invasive mole in the uterus and a corpus luteum in the right ovary. The shaded area represents an undetectable level. hCG = open circle, relaxin = closed circle.
Results

Relaxin and hCG levels before treatment

Serum relaxin was detectable before treatment in all 6 patients. The relaxin and hCG concentrations were lower in these patients than in normal women during the first trimester of pregnancy or in patients with hydatidiform mole (Table 1). There was an overlap in the range of hCG values, but not in that of relaxin values between these patients and those with hydatidiform mole (Table 1).

Case Reports

Invasive mole

In a patient with invasive mole, relaxin levels decreased to an undetectable level 3 days after a total hysterectomy and right salpingo-oophorectomy (Fig. 1). hCG levels also rapidly decreased, though they were still detectable 3 weeks after operation. A corpus luteum was confirmed by histology in the right ovary.

Choriocarcinoma

A patient with nonmetastatic choriocarcinoma was characterized by a plateau in both hCG and relaxin levels after evacuation (Fig. 2). A discordant hCG and relaxin profile was noticed. Although relaxin levels later decreased to an undetectable level, low but detectable levels of hCG persisted. Then hCG levels showed a rise, followed by a small rise in relaxin levels. After a total hysterectomy and bilateral salpingo-oophorectomy, hCG levels fell rap-
idly, but still detectable until 12 days after operation. Relaxin levels became undetectable 3 days after operation. A corpus luteum was confirmed by histology in the right ovary.

In a patient with metastatic choriocarcinoma, hCG rapidly decreased after initiation of chemotherapy, while relaxin slowly decreased (Fig. 3).

**Persistent trophoblastic disease**

In a patient with postmolar persistent trophoblastic disease, the fall in hCG and relaxin levels was retarded after evacuation (Fig. 4). hCG and relaxin levels did not fall to an undetectable level, and rose later. On initiation of chemotherapy, both relaxin and hCG levels fell. Although relaxin became undetectable within 12 days, hCG did not become undetectable over 2 months.

In a patient with nonmetastatic persistent trophoblastic disease, relaxin levels were low but detectable (0.2 ng/ml) before treatment (Fig. 5). hCG levels fell steadily during chemotherapy. Relaxin levels were always undetectable after initiation of chemotherapy.

**Discussion**

Detectable levels of relaxin were found in patients with invasive mole, choriocarcinoma and persistent trophoblastic disease. The corpus luteum of pregnancy is the main...
source of circulating immunoreactive relaxin in normal pregnancy (Weiss et al., 1976). In the 2 patients with trophoblastic disease who underwent a total hysterectomy and excirpation of the ovary containing a corpus luteum, relaxin levels promptly fell and became undetectable within 3 days. On the other hand, the disappearance pattern of relaxin was slower in a patient with metastatic choriocarcinoma treated with chemotherapy. In 1 of the 2 patients with persistent trophoblastic disease, serum relaxin levels were still elevated 5 days after the initiation of chemotherapy. Therefore, the corpus luteum may also be the main source of circulating immunoreactive relaxin in trophoblastic disease, though an extraluteal source of relaxin cannot be excluded. Relaxin was always undetectable after initiation of chemotherapy in a patient with persistent trophoblastic disease. This may be accounted for by the patient's pretreatment relaxin level which was the lowest among the patients studied. Parallel changes in relaxin and hCG levels were, in general, observed during the course of trophoblastic disease. This finding suggests, but does not prove, that relaxin secretion is dependent on hCG stimulation in trophoblastic disease in the presence of corpus luteum. Serum relaxin levels before treatment were significantly lower in trophoblastic disease than in normal or molar pregnancy. This may be accounted for by the significantly lower hCG

![Graph](image-url)

Fig. 4. A 34-year-old woman, gravida 4, para 2, underwent evacuation of an hydatidiform mole on April 19, 1983. The titers before evacuation were 650,000 mIU/ml for hCG and 0.8 ng/ml for relaxin. After evacuation, both hCG and relaxin levels fell slowly through September, 1983. However, they plateaued in October, 1983, and increased in November, 1983. Five day courses of methotrexate, actinomycin and cyclophosphamide (MAC) therapy were begun on 5 occasions from December 25, 1983 to April 23, 1984. The shaded area represents an undetectable level. hCG = open circle, relaxin = closed circle.
level found in our patients with trophoblastic
disease compared to normal or molar preg-
nancy. In a patient with postmolar persist-
ent trophoblastic disease, detectable levels
of relaxin were found for 8 months after
evacuation of hydatidiform mole. Conse-
quently, the function of the corpus luteum
in secreting relaxin may continue as long
as stimulation of the corpus luteum by effec-
tive hCG persists. While hCG can induce
luteal relaxin secretion, constant doses of
hCG or luteinizing hormone cannot main-
tain the nonpregnant corpus luteum for more
than 2 additional weeks (Strott et al., 1969;
Hanson et al., 1971; Stock et al., 1971).
Thus, additional factors may be present to
account for the continued function of the
corpus luteum in secreting relaxin in tro-
phoblastic disease.

References

Hanson, F. W., Z. E. Powell and V. C. Stevens
(1971). Effects of HCG and human pituitary
LH on steroid secretion and functional life of
Metab. 32, 211–215.

O’Byrne, E. M., B. T. Carriere, I. Sorensen, S.
Plasma immunoreactive relaxin levels in preg-
nant and nonpregnant women. J. Clin. Endo-
crinol. Metab. 47, 1106–1110.

O’Byrne, E. M. and B. G. Steinetz (1976). Ra-
dioimmunoassay (RIA) of relaxin in sera of
various species using an antiserum to porcine
276.

Quagliarello, J., L. Goldsmith, B. G. Steinetz, D.
D. Lustig and G. Weiss (1980). Induction of
relaxin secretion in nonpregnant women by
human chorionic gonadotropin. J. Clin. Endo-
crinol. Metab. 51, 74–77.

Quagliarello, J., N. Szlachter, B. G. Steinetz, L.


